Clinical Trials Logo

Filter by:
NCT ID: NCT05404516 Recruiting - Clinical trials for Core Binding Factor Acute Myeloid Leukemia

Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML

Start date: January 1, 2020
Phase: Phase 2
Study type: Interventional

Core-binding factor acute myeloid leukemia accounts for 10-15% of AML and is categorized as favorable-risk AML. However, the 5-year CIR was up to 40% in this group of patients. Emerging data show that a high frequency of mutations and/or high expression of KIT in CBF AML. Sorafenib is a multitargeted TKI, thus the purpose of this study is to evaluate the safety and efficacy of sorafenib combined with standard therapy in CBF AML.

NCT ID: NCT05404256 Recruiting - Pancreatic Fistula Clinical Trials

Comparison of Effectiveness of TissuePatchTM in Preventing Postoperative Pancreatic Fistula

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

Postoperative pancreatic fistula is one of the most serious complications after gastric cancer surgery and can lead to surgery-related death. Postoperative pancreatic fistula for gastric cancer often occurs in accidental injury of pancreas during peripancreatic lymph node dissection, blunt separation of pancreatic capsule injury, laparoscopic instrument clamp and long-term compression of pancreas, etc. TissePatchTM is a synthetic, self-adhesive, absorbable surgical sealant and barrier used to seal and reinforce wounds and prevent leakage of air, blood, and fluid during neurosurgery, spine, chest, and soft tissue surgery. Therefore, we proposed whether the use of TissuePatchTM can reduce the occurrence of pancreatic fistula after gastric cancer surgery, and the clinical trial of the effectiveness of TissuePatchTM on the prevention of pancreatic fistula after radical gastrectomy of gastric cancer can provide new clinical data for the prevention of pancreatic fistula after gastric cancer surgery, and help reduce a series of adverse reactions caused by pancreatic fistula in patients.

NCT ID: NCT05403905 Recruiting - Clinical trials for Osteoarthritis, Knee

A Cohort Study of Non-surgical Treatment and Exercise Rehabilitation in Patients With Anterior Cruciate Ligament Rupture

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

This clinical trial compared the prognosis of surgical and non-surgical treatment in patients with complete anterior cruciate ligament rupture

NCT ID: NCT05403775 Recruiting - Clinical trials for Lumbar Spinal Stenosis

Application of 3D Printing Guide Plate in Dorsal Root Ganglion Intervention Treatments

Start date: July 8, 2022
Phase: N/A
Study type: Interventional

This study applies 3D-printed customized guide plate in assisting the accurate puncture in transforaminal epidural steroid injection (TFESI) combined with pulsed radiofrequency (PRF) treatment. This technique can shorten reduce the intra-operative radiation, and do not affect the surgical outcome.

NCT ID: NCT05403242 Recruiting - Clinical trials for Advanced Gastroesophageal Adenocarcinoma

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Start date: September 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study was a single-arm, open, multi-center Phase Ib/II clinical trial to observe and evaluate the efficacy and safety of RC48-ADC plus S-1 in first-line treatment of advanced gastroesophageal adenocarcinoma with moderate expression of HER2.

NCT ID: NCT05403216 Recruiting - Oral Lichen Planus Clinical Trials

Relationship Between Oral Lichen Planus and Autoimmune Thyroid Diseases

Start date: December 1, 2022
Phase:
Study type: Observational

On the basis of previous studies, a validation cohort will be established to explore the relationship between oral lichen planus and autoimmune thyroid diseases, and a disease efficacy prediction strategy can be formed.

NCT ID: NCT05403138 Recruiting - Clinical trials for Neuromyelitis Optica

Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders

DAWN
Start date: November 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The objectives of this time-to-event study were to assess the efficacy and safety of Daratumumab as compared with placebo in participants with neuromyelitis optica spectrum disorder (NMOSD) who were anti-aquaporin-4 (AQP4) antibody-positive. NMOSD is an autoimmune disease of the central nervous system that predominantly affects the spinal cord, optic nerves, and area postrema. It is usually mediated by the pathogenic AQP4-IgG. Antibody-secreting cells (ASCs) have been recognized as essential sources of AQP4-IgG. CD38 is a glycoprotein that is highly expressed on ASCs. Daratumumab, a CD38-directed monoclonal antibody, has been shown to decrease the levels of autoantibodies in lupus, myasthenia gravis, or autoimmune encephalitis. This randomized controlled study aims to evaluate the therapeutic potential of daratumumab in NMOSD.

NCT ID: NCT05402839 Recruiting - Clinical trials for Malignant Hyperthermia

Screening of Malignant Hyperthermia Susceptible Individuals

Start date: February 22, 2022
Phase:
Study type: Observational [Patient Registry]

This study intends to target patients who underwent surgery under general anesthesia during the study period and developed malignant hyperthermia during or after surgery. Therefore, the total sample size was estimated to be about 50 people based on the past incidence of this rare disease. Every year, about 20 patients and their families who developed malignant hyperthermia during or after surgery will participate in this nationwide study (estimated by the current incidence of malignant hyperthermia), and about 1-5 patients will be admitted to Peking University Third Hospital participate in this research. Relevant specimens were collected from malignant hyperthermia (MH) patients and their family members for genetic analysis to determine the mutation of MH-related pathogenic gene loci.

NCT ID: NCT05402722 Recruiting - Clinical trials for TNBC - Triple-Negative Breast Cancer

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer.

NCT ID: NCT05402670 Recruiting - Clinical trials for Gastric Mucosal Manifestations in Patients With Dermatomyositis

Gastric Mucosal Changes in Patients With Dermatomyositis

Start date: June 1, 2022
Phase:
Study type: Observational

There are a large number of reports in the literature that patients with dermatomyositis often have various malignant tumors, and reports of gastric cancer are not rare. At present, the widely recognized gastric cancer occurrence patterns are: normal gastric mucosa-chronic superficial gastritis-chronic atrophic gastritis-intestinal metaplasia-dysplasia-gastric cancer, so the research about the gastric mucosal performance of patients with dermatomyositis is clinically meaningful